Methods for treating hepcidin-mediated disorders
By administering an IL-6 antagonist to patients with the TMPRSS6 rs855791 major allele, we address the deficiencies of existing technologies for treating hepcidin-mediated conditions and achieve effective therapeutic effects in specific patient populations, including increased hemoglobin content and reduced cardiovascular risk.
Patent Information
- Application Number
- CN202110454211.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2015-12-17
- Filing Date
- 2016-07-28
- Publication Date
- 2025-09-12
- Estimated Expiration
- 2036-08-24
AI Technical Summary
Existing technologies have failed to effectively treat conditions mediated by hepcidin, such as anemia of chronic disease, chronic inflammatory diseases, and cancer, especially in patients with the TMPRSS6 rs855791 major allele, where the therapeutic effect of IL-6 signaling is limited.
Provided are methods for administering a therapeutically effective amount of an IL-6 antagonist to a patient suffering from a hepcidin-mediated disorder, particularly a patient having the TMPRSS6 rs855791 major allele, to improve the disorder by reducing IL-6 signaling, including administering the IL-6 antagonist and interrupting treatment as needed to reduce side effects and costs.
In patients with the TMPRSS6 rs855791 major allele, IL-6 antagonists significantly increased hemoglobin content and hematocrit, reduced the use of erythropoiesis-stimulating agents, reduced the risk of cardiovascular death, and improved symptoms of chronic diseases.